Radiotherapy quality assurance of patients with squamous cell carcinoma of the head and neck included in the DAHANCA 19 randomised phase III trial
The treatment plans in DAHANCA 19 adhered well to national guidelines. Most major deviations were observed in the experimental arm but did not affect the local treatment control. No indication that compromised RT-QA affected the conclusions of DAHANCA 19 was found.
Authors
- Bob Smulders
- Kenneth Jensen (ORCID: https://orcid.org/0000-0002-2364-965X)
- Jesper Grau Eriksen (ORCID: https://orcid.org/0000-0002-1145-6033)
- Eva Samsøe (ORCID: https://orcid.org/0000-0002-8011-669X)
- A. I. S. Holm (ORCID: https://orcid.org/0009-0006-7648-6600)
- Claus Andrup Kristensen (ORCID: https://orcid.org/0000-0002-6250-0161)
- Cai Grau (ORCID: https://orcid.org/0000-0003-3548-3527)
- Maria Andersen (ORCID: https://orcid.org/0000-0003-2883-2450)
- Jens Overgaard (ORCID: https://orcid.org/0000-0002-0814-8179)
- Christian Maare (ORCID: https://orcid.org/0000-0002-9698-2082)
- Christian Rønn Hansen (ORCID: https://orcid.org/0000-0001-5716-6069)
- Jørgen Johansen (ORCID: https://orcid.org/0000-0003-3911-3929)
- Å. Bratland
- Torbjørn Furre (ORCID: https://orcid.org/0000-0003-3930-8822)
- Hella Maria Brøgger Sand
Institutions
- Oslo University Hospital (NO)
- University of Southern Denmark (DK)
- Aalborg University Hospital (DK)
- Odense University Hospital (DK)
- Aarhus University Hospital (DK)
- Copenhagen University Hospital (DK)
- Gentofte Hospital (DK)
- Danish Pain Research Center (DK)
Publication Details
- Journal
- Radiotherapy and Oncology
- Published
- 2025-08-18
- DOI
- https://doi.org/10.1016/j.radonc.2025.111096
- Citations
- 1
- Primary Topic
- Advanced Radiotherapy Techniques
- Type
- article
- Field-Weighted Citation Impact
- 1.88
Funders
- Novo Nordisk
- Novo Nordisk Fonden